Published in Proc Natl Acad Sci U S A on August 23, 2002
Prevalence of quadruplexes in the human genome. Nucleic Acids Res (2005) 7.79
Quadruplex DNA: sequence, topology and structure. Nucleic Acids Res (2006) 6.42
G-quadruplexes in promoters throughout the human genome. Nucleic Acids Res (2006) 5.84
Highly prevalent putative quadruplex sequence motifs in human DNA. Nucleic Acids Res (2005) 5.34
Quantitative visualization of DNA G-quadruplex structures in human cells. Nat Chem (2013) 4.61
An RNA G-quadruplex in the 5' UTR of the NRAS proto-oncogene modulates translation. Nat Chem Biol (2007) 4.11
Human telomeric sequence forms a hybrid-type intramolecular G-quadruplex structure with mixed parallel/antiparallel strands in potassium solution. Nucleic Acids Res (2006) 3.87
Propeller-type parallel-stranded G-quadruplexes in the human c-myc promoter. J Am Chem Soc (2004) 3.74
Targeting G-quadruplexes in gene promoters: a novel anticancer strategy? Nat Rev Drug Discov (2011) 3.54
Human telomere, oncogenic promoter and 5'-UTR G-quadruplexes: diverse higher order DNA and RNA targets for cancer therapeutics. Nucleic Acids Res (2007) 3.49
Putative DNA quadruplex formation within the human c-kit oncogene. J Am Chem Soc (2005) 3.28
DNA secondary structures: stability and function of G-quadruplex structures. Nat Rev Genet (2012) 3.15
Gene function correlates with potential for G4 DNA formation in the human genome. Nucleic Acids Res (2006) 3.13
G-quadruplex formation within the promoter of the KRAS proto-oncogene and its effect on transcription. Nucleic Acids Res (2006) 3.09
Facilitation of a structural transition in the polypurine/polypyrimidine tract within the proximal promoter region of the human VEGF gene by the presence of potassium and G-quadruplex-interactive agents. Nucleic Acids Res (2005) 3.01
FANCJ helicase defective in Fanconia anemia and breast cancer unwinds G-quadruplex DNA to defend genomic stability. Mol Cell Biol (2008) 2.88
Studies on the structure and dynamics of the human telomeric G quadruplex by single-molecule fluorescence resonance energy transfer. Proc Natl Acad Sci U S A (2003) 2.82
A conserved quadruplex motif located in a transcription activation site of the human c-kit oncogene. Biochemistry (2006) 2.62
Not so crystal clear: the structure of the human telomere G-quadruplex in solution differs from that present in a crystal. Nucleic Acids Res (2005) 2.57
Small-molecule-induced DNA damage identifies alternative DNA structures in human genes. Nat Chem Biol (2012) 2.41
Structures, folding patterns, and functions of intramolecular DNA G-quadruplexes found in eukaryotic promoter regions. Biochimie (2008) 2.38
Non-B DNA structure-induced genetic instability and evolution. Cell Mol Life Sci (2009) 2.37
An alternative DNA structure is necessary for pilin antigenic variation in Neisseria gonorrhoeae. Science (2009) 2.37
5'-UTR RNA G-quadruplexes: translation regulation and targeting. Nucleic Acids Res (2012) 2.36
Human telomeric DNA: G-quadruplex, i-motif and Watson-Crick double helix. Nucleic Acids Res (2002) 2.35
Biophysical and biological properties of quadruplex oligodeoxyribonucleotides. Nucleic Acids Res (2003) 2.34
Conserved elements with potential to form polymorphic G-quadruplex structures in the first intron of human genes. Nucleic Acids Res (2008) 2.27
Structure of an unprecedented G-quadruplex scaffold in the human c-kit promoter. J Am Chem Soc (2007) 2.26
G-quadruplexes: the beginning and end of UTRs. Nucleic Acids Res (2008) 2.18
Genome-wide prediction of G4 DNA as regulatory motifs: role in Escherichia coli global regulation. Genome Res (2006) 2.12
The effect of chemical modifications on the thermal stability of different G-quadruplex-forming oligonucleotides. Nucleic Acids Res (2005) 2.04
NMR solution structure of the major G-quadruplex structure formed in the human BCL2 promoter region. Nucleic Acids Res (2006) 2.03
The importance of negative superhelicity in inducing the formation of G-quadruplex and i-motif structures in the c-Myc promoter: implications for drug targeting and control of gene expression. J Med Chem (2009) 2.03
Small-molecule interaction with a five-guanine-tract G-quadruplex structure from the human MYC promoter. Nat Chem Biol (2005) 2.00
Influence of loop size on the stability of intramolecular DNA quadruplexes. Nucleic Acids Res (2004) 1.99
Genomic distribution and functional analyses of potential G-quadruplex-forming sequences in Saccharomyces cerevisiae. Nucleic Acids Res (2007) 1.98
The disease-associated r(GGGGCC)n repeat from the C9orf72 gene forms tract length-dependent uni- and multimolecular RNA G-quadruplex structures. J Biol Chem (2013) 1.97
DNA architecture: from G to Z. Curr Opin Struct Biol (2006) 1.97
Deconvoluting the structural and drug-recognition complexity of the G-quadruplex-forming region upstream of the bcl-2 P1 promoter. J Am Chem Soc (2006) 1.93
Trisubstituted isoalloxazines as a new class of G-quadruplex binding ligands: small molecule regulation of c-kit oncogene expression. J Am Chem Soc (2007) 1.87
High-throughput sequencing of DNA G-quadruplex structures in the human genome. Nat Biotechnol (2015) 1.86
A sequence-independent study of the influence of short loop lengths on the stability and topology of intramolecular DNA G-quadruplexes. Biochemistry (2007) 1.75
G-quadruplex nucleic acids as therapeutic targets. Curr Opin Chem Biol (2009) 1.74
Identification and characterization of nucleolin as a c-myc G-quadruplex-binding protein. J Biol Chem (2009) 1.72
Design, synthesis and biological evaluation of a novel class of anticancer agents: anthracenylisoxazole lexitropsin conjugates. Bioorg Med Chem (2008) 1.71
The role of supercoiling in transcriptional control of MYC and its importance in molecular therapeutics. Nat Rev Cancer (2009) 1.71
Characterization of the G-quadruplexes in the duplex nuclease hypersensitive element of the PDGF-A promoter and modulation of PDGF-A promoter activity by TMPyP4. Nucleic Acids Res (2007) 1.66
Formation of pseudosymmetrical G-quadruplex and i-motif structures in the proximal promoter region of the RET oncogene. J Am Chem Soc (2007) 1.53
Preferential binding of a G-quadruplex ligand to human chromosome ends. Nucleic Acids Res (2005) 1.53
Formation of the G-quadruplex and i-motif structures in retinoblastoma susceptibility genes (Rb). Nucleic Acids Res (2006) 1.49
The interaction of telomeric DNA and C-myc22 G-quadruplex with 11 natural alkaloids. Nucleic Acid Ther (2012) 1.49
Engineering the quadruplex fold: nucleoside conformation determines both folding topology and molecularity in guanine quadruplexes. J Am Chem Soc (2006) 1.49
5'-UTR G-quadruplex structures acting as translational repressors. Nucleic Acids Res (2010) 1.49
A novel G-quadruplex-forming GGA repeat region in the c-myb promoter is a critical regulator of promoter activity. Nucleic Acids Res (2008) 1.49
Altered gene expression in the Werner and Bloom syndromes is associated with sequences having G-quadruplex forming potential. Nucleic Acids Res (2009) 1.44
Structural insights into G-quadruplexes: towards new anticancer drugs. Future Med Chem (2010) 1.44
The proximal promoter region of the human vascular endothelial growth factor gene has a G-quadruplex structure that can be targeted by G-quadruplex-interactive agents. Mol Cancer Ther (2008) 1.44
G-quadruplexes and their regulatory roles in biology. Nucleic Acids Res (2015) 1.43
Formation of a unique end-to-end stacked pair of G-quadruplexes in the hTERT core promoter with implications for inhibition of telomerase by G-quadruplex-interactive ligands. J Am Chem Soc (2009) 1.42
Multitasking in the mitochondrion by the ATP-dependent Lon protease. Biochim Biophys Acta (2011) 1.41
A G-rich sequence within the c-kit oncogene promoter forms a parallel G-quadruplex having asymmetric G-tetrad dynamics. J Am Chem Soc (2009) 1.40
Genome-wide analysis reveals regulatory role of G4 DNA in gene transcription. Genome Res (2007) 1.39
Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect. J Clin Invest (2007) 1.39
Structural revisions of small molecules reported to cross-link G-quadruplex DNA in vivo reveal a repetitive assignment error in the literature. Sci Rep (2016) 1.38
Telomerase downregulation induced by the G-quadruplex ligand 12459 in A549 cells is mediated by hTERT RNA alternative splicing. Nucleic Acids Res (2004) 1.38
Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice. Cancer Chemother Pharmacol (2008) 1.38
Nucleolin directly mediates Epstein-Barr virus immune evasion through binding to G-quadruplexes of EBNA1 mRNA. Nat Commun (2017) 1.38
QuadBase: genome-wide database of G4 DNA--occurrence and conservation in human, chimpanzee, mouse and rat promoters and 146 microbes. Nucleic Acids Res (2007) 1.35
Inhibition of translation in living eukaryotic cells by an RNA G-quadruplex motif. RNA (2008) 1.34
Metastases suppressor NM23-H2 interaction with G-quadruplex DNA within c-MYC promoter nuclease hypersensitive element induces c-MYC expression. Nucleic Acids Res (2008) 1.34
TLS/FUS (translocated in liposarcoma/fused in sarcoma) regulates target gene transcription via single-stranded DNA response elements. Proc Natl Acad Sci U S A (2012) 1.33
Kinetics and mechanism of K+- and Na+-induced folding of models of human telomeric DNA into G-quadruplex structures. Nucleic Acids Res (2008) 1.33
G4 resolvase 1 binds both DNA and RNA tetramolecular quadruplex with high affinity and is the major source of tetramolecular quadruplex G4-DNA and G4-RNA resolving activity in HeLa cell lysates. J Biol Chem (2008) 1.32
Intramolecular DNA quadruplexes with different arrangements of short and long loops. Nucleic Acids Res (2007) 1.30
Formation of a G-quadruplex at the BCL2 major breakpoint region of the t(14;18) translocation in follicular lymphoma. Nucleic Acids Res (2010) 1.30
New insights into replication origin characteristics in metazoans. Cell Cycle (2012) 1.29
Targeting MYC Expression through G-Quadruplexes. Genes Cancer (2010) 1.29
Role for G-quadruplex RNA binding by Epstein-Barr virus nuclear antigen 1 in DNA replication and metaphase chromosome attachment. J Virol (2009) 1.29
Evidence of genome-wide G4 DNA-mediated gene expression in human cancer cells. Nucleic Acids Res (2009) 1.28
Quadfinder: server for identification and analysis of quadruplex-forming motifs in nucleotide sequences. Nucleic Acids Res (2006) 1.26
Small-molecule-mediated G-quadruplex isolation from human cells. Nat Chem (2010) 1.26
Single-molecule conformational analysis of G-quadruplex formation in the promoter DNA duplex of the proto-oncogene c-kit. J Am Chem Soc (2007) 1.25
Role of TLS DNA polymerases eta and kappa in processing naturally occurring structured DNA in human cells. Mol Carcinog (2009) 1.24
Sequence occurrence and structural uniqueness of a G-quadruplex in the human c-kit promoter. Nucleic Acids Res (2007) 1.24
Predicting and understanding the stability of G-quadruplexes. Bioinformatics (2009) 1.23
Multiple biochemical activities of NM23/NDP kinase in gene regulation. J Bioenerg Biomembr (2003) 1.23
Single-molecule detection of folding and unfolding of the G-quadruplex aptamer in a nanopore nanocavity. Nucleic Acids Res (2008) 1.22
Biophysical studies of the c-MYC NHE III1 promoter: model quadruplex interactions with a cationic porphyrin. Biophys J (2006) 1.20
Formation and properties of hairpin and tetraplex structures of guanine-rich regulatory sequences of muscle-specific genes. Nucleic Acids Res (2005) 1.20
G-quadruplex structures contribute to the neuroprotective effects of angiogenin-induced tRNA fragments. Proc Natl Acad Sci U S A (2014) 1.20
Potential in vivo roles of nucleic acid triple-helices. RNA Biol (2011) 1.20
NM23-H2 may play an indirect role in transcriptional activation of c-myc gene expression but does not cleave the nuclease hypersensitive element III(1). Mol Cancer Ther (2009) 1.19
Therapeutic strategies to inhibit MYC. Cold Spring Harb Perspect Med (2014) 1.19
c-MYC promoter G-quadruplex formed at the 5'-end of NHE III1 element: insights into biological relevance and parallel-stranded G-quadruplex stability. Nucleic Acids Res (2011) 1.18
Solution structure of a 2:1 quindoline-c-MYC G-quadruplex: insights into G-quadruplex-interactive small molecule drug design. J Am Chem Soc (2011) 1.17
Protein hnRNP A1 and its derivative Up1 unfold quadruplex DNA in the human KRAS promoter: implications for transcription. Nucleic Acids Res (2009) 1.16
Biochemical techniques for the characterization of G-quadruplex structures: EMSA, DMS footprinting, and DNA polymerase stop assay. Methods Mol Biol (2010) 1.16
Intramolecularly folded G-quadruplex and i-motif structures in the proximal promoter of the vascular endothelial growth factor gene. Nucleic Acids Res (2008) 1.16
Genome-wide analysis of a G-quadruplex-specific single-chain antibody that regulates gene expression. Nucleic Acids Res (2009) 1.15
Targeting human gastrointestinal stromal tumor cells with a quadruplex-binding small molecule. J Med Chem (2009) 1.15
Identification of c-MYC as a target of the APC pathway. Science (1998) 24.25
The structure of DNA. Cold Spring Harb Symp Quant Biol (1953) 15.08
Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature (1992) 7.61
Site-specific oligonucleotide binding represses transcription of the human c-myc gene in vitro. Science (1988) 5.97
Chromatin structure and protein binding in the putative regulatory region of the c-myc gene in Burkitt lymphoma. Cell (1984) 5.61
myc function and regulation. Annu Rev Biochem (1992) 5.33
DNA and its associated processes as targets for cancer therapy. Nat Rev Cancer (2002) 4.69
Control of c-myc regulation in normal and neoplastic cells. Adv Cancer Res (1991) 4.60
DNA tetraplex formation in the control region of c-myc. Nucleic Acids Res (1998) 4.09
An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation. Mol Cell Biol (1988) 4.08
Human c-myc transcription factor PuF identified as nm23-H2 nucleoside diphosphate kinase, a candidate suppressor of tumor metastasis. Science (1993) 3.32
The molecular role of Myc in growth and transformation: recent discoveries lead to new insights. FASEB J (1998) 2.86
Inhibition of human telomerase by a G-quadruplex-interactive compound. J Med Chem (1997) 2.66
MAZ, a zinc finger protein, binds to c-MYC and C2 gene sequences regulating transcriptional initiation and termination. Proc Natl Acad Sci U S A (1992) 2.40
The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Mol Cancer Ther (2002) 2.39
Diverse molecular interactions of the hnRNP K protein. FEBS Lett (1997) 2.35
Unusual DNA structures. J Biol Chem (1988) 2.29
Cellular nucleic acid binding protein regulates the CT element of the human c-myc protooncogene. J Biol Chem (1995) 2.12
Three-dimensional solution structure of the thrombin-binding DNA aptamer d(GGTTGGTGTGGTTGG). J Mol Biol (1994) 2.03
Selective interactions of cationic porphyrins with G-quadruplex structures. J Am Chem Soc (2001) 1.91
Activating transcription from single stranded DNA. Proc Natl Acad Sci U S A (1996) 1.87
DNA structure equilibria in the human c-myc gene. Biochemistry (1987) 1.81
c-myc antisense transcripts accelerate differentiation and inhibit G1 progression in murine erythroleukemia cells. Mol Cell Biol (1988) 1.76
Action of Myc in vivo - proliferation and apoptosis. Curr Opin Genet Dev (2000) 1.69
A DNA polymerase stop assay for G-quadruplex-interactive compounds. Nucleic Acids Res (1999) 1.68
Reconciliation of the X-ray and NMR structures of the thrombin-binding aptamer d(GGTTGGTGTGGTTGG). J Mol Biol (1996) 1.66
Unusual DNA structure of the diabetes susceptibility locus IDDM2 and its effect on transcription by the insulin promoter factor Pur-1/MAZ. Proc Natl Acad Sci U S A (2000) 1.59
Structure-activity of tetrad-forming oligonucleotides as a potent anti-HIV therapeutic drug. J Biol Chem (1998) 1.57
A nuclease hypersensitive element in the human c-myc promoter adopts several distinct i-tetraplex structures. Biochem Biophys Res Commun (2000) 1.52
Human NM23/nucleoside diphosphate kinase regulates gene expression through DNA binding to nuclease-hypersensitive transcriptional elements. J Bioenerg Biomembr (2000) 1.39
Suppression of human immunodeficiency virus type 1 activity in vitro by oligonucleotides which form intramolecular tetrads. J Biol Chem (1995) 1.36
The development and use of a DNA polymerase arrest assay for the evaluation of parameters affecting intrastrand tetraplex formation. J Biol Chem (1996) 1.36
Catalysis of DNA cleavage and nucleoside triphosphate synthesis by NM23-H2/NDP kinase share an active site that implies a DNA repair function. Proc Natl Acad Sci U S A (2000) 1.33
NM23-H1 and NM23-H2 repress transcriptional activities of nuclease-hypersensitive elements in the platelet-derived growth factor-A promoter. J Biol Chem (2001) 1.28
The transcription factor, Nm23H2, binds to and activates the translocated c-myc allele in Burkitt's lymphoma. J Biol Chem (1995) 1.26
A human NDP-kinase B specifically binds single-stranded poly-pyrimidine sequences. Nucleic Acids Res (1995) 1.23
Structure-based mutational and functional analysis identify human NM23-H2 as a multifunctional enzyme. Biochemistry (2002) 1.21
DNA and associated targets for drug design. J Med Chem (1989) 1.20
c-Myc is necessary for DNA damage-induced apoptosis in the G(2) phase of the cell cycle. Mol Cell Biol (2001) 1.19
Potassium-induced loop conformational transition of a potent anti-HIV oligonucleotide. J Biomol Struct Dyn (1997) 1.16
Max and inhibitory c-Myc mutants induce erythroid differentiation and resistance to apoptosis in human myeloid leukemia cells. Oncogene (1997) 1.15
Telomere-interactive agents affect proliferation rates and induce chromosomal destabilization in sea urchin embryos. Anticancer Drug Des (1999) 1.11
c-myc Suppression in Burkitt's lymphoma cells. Biochem Biophys Res Commun (2002) 1.07
Binding of THZif-1, a MAZ-like zinc finger protein to the nuclease-hypersensitive element in the promoter region of the c-MYC protooncogene. J Biol Chem (1996) 1.05
DNA conformation, topology, and the regulation of c-myc expression. Curr Top Microbiol Immunol (1997) 1.04
Targeting G-quadruplexes in gene promoters: a novel anticancer strategy? Nat Rev Drug Discov (2011) 3.54
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
The dynamic character of the G-quadruplex element in the c-MYC promoter and modification by TMPyP4. J Am Chem Soc (2004) 3.19
Facilitation of a structural transition in the polypurine/polypyrimidine tract within the proximal promoter region of the human VEGF gene by the presence of potassium and G-quadruplex-interactive agents. Nucleic Acids Res (2005) 3.01
Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res (2002) 2.55
The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Mol Cancer Ther (2002) 2.39
Structures, folding patterns, and functions of intramolecular DNA G-quadruplexes found in eukaryotic promoter regions. Biochimie (2008) 2.38
Evidence for the presence of a guanine quadruplex forming region within a polypurine tract of the hypoxia inducible factor 1alpha promoter. Biochemistry (2005) 2.27
NMR solution structure of the major G-quadruplex structure formed in the human BCL2 promoter region. Nucleic Acids Res (2006) 2.03
The importance of negative superhelicity in inducing the formation of G-quadruplex and i-motif structures in the c-Myc promoter: implications for drug targeting and control of gene expression. J Med Chem (2009) 2.03
Deconvoluting the structural and drug-recognition complexity of the G-quadruplex-forming region upstream of the bcl-2 P1 promoter. J Am Chem Soc (2006) 1.93
Targeting Axl and Mer kinases in cancer. Mol Cancer Ther (2011) 1.88
Telomestatin and diseleno sapphyrin bind selectively to two different forms of the human telomeric G-quadruplex structure. J Am Chem Soc (2005) 1.87
Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular g-quadruplex. J Am Chem Soc (2002) 1.82
The role of supercoiling in transcriptional control of MYC and its importance in molecular therapeutics. Nat Rev Cancer (2009) 1.71
Characterization of the G-quadruplexes in the duplex nuclease hypersensitive element of the PDGF-A promoter and modulation of PDGF-A promoter activity by TMPyP4. Nucleic Acids Res (2007) 1.66
The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer. Mol Cancer Ther (2004) 1.65
Formation of pseudosymmetrical G-quadruplex and i-motif structures in the proximal promoter region of the RET oncogene. J Am Chem Soc (2007) 1.53
A novel G-quadruplex-forming GGA repeat region in the c-myb promoter is a critical regulator of promoter activity. Nucleic Acids Res (2008) 1.49
The proximal promoter region of the human vascular endothelial growth factor gene has a G-quadruplex structure that can be targeted by G-quadruplex-interactive agents. Mol Cancer Ther (2008) 1.44
Formation of a unique end-to-end stacked pair of G-quadruplexes in the hTERT core promoter with implications for inhibition of telomerase by G-quadruplex-interactive ligands. J Am Chem Soc (2009) 1.42
Design and synthesis of an expanded porphyrin that has selectivity for the c-MYC G-quadruplex structure. J Am Chem Soc (2005) 1.40
The c-MYC NHE III(1): function and regulation. Annu Rev Pharmacol Toxicol (2010) 1.31
Targeting MYC Expression through G-Quadruplexes. Genes Cancer (2010) 1.29
Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma. Mol Cancer Ther (2003) 1.26
The different biological effects of telomestatin and TMPyP4 can be attributed to their selectivity for interaction with intramolecular or intermolecular G-quadruplex structures. Cancer Res (2003) 1.25
Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol Cancer Ther (2004) 1.24
Targeting Aurora-2 kinase in cancer. Mol Cancer Ther (2003) 1.23
Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma. Clin Cancer Res (2004) 1.21
Structure of the biologically relevant G-quadruplex in the c-MYC promoter. Nucleosides Nucleotides Nucleic Acids (2006) 1.21
Biophysical studies of the c-MYC NHE III1 promoter: model quadruplex interactions with a cationic porphyrin. Biophys J (2006) 1.20
NM23-H2 may play an indirect role in transcriptional activation of c-myc gene expression but does not cleave the nuclease hypersensitive element III(1). Mol Cancer Ther (2009) 1.19
Solution structure of a 2:1 quindoline-c-MYC G-quadruplex: insights into G-quadruplex-interactive small molecule drug design. J Am Chem Soc (2011) 1.17
Telomere inhibition and telomere disruption as processes for drug targeting. Annu Rev Pharmacol Toxicol (2002) 1.17
Biochemical techniques for the characterization of G-quadruplex structures: EMSA, DMS footprinting, and DNA polymerase stop assay. Methods Mol Biol (2010) 1.16
Intramolecularly folded G-quadruplex and i-motif structures in the proximal promoter of the vascular endothelial growth factor gene. Nucleic Acids Res (2008) 1.16
Demonstration that drug-targeted down-regulation of MYC in non-Hodgkins lymphoma is directly mediated through the promoter G-quadruplex. J Biol Chem (2011) 1.14
Telomeres and telomerases as drug targets. Curr Opin Pharmacol (2002) 1.14
Dietary administration of the proapoptotic vitamin E analogue alpha-tocopheryloxyacetic acid inhibits metastatic murine breast cancer. Cancer Res (2006) 1.11
The cationic porphyrin TMPyP4 destabilizes the tetraplex form of the fragile X syndrome expanded sequence d(CGG)n. Nucleic Acids Res (2003) 1.09
The C-terminus of nucleolin promotes the formation of the c-MYC G-quadruplex and inhibits c-MYC promoter activity. Biochemistry (2010) 1.07
The dynamic character of the BCL2 promoter i-motif provides a mechanism for modulation of gene expression by compounds that bind selectively to the alternative DNA hairpin structure. J Am Chem Soc (2014) 1.06
Molecular cloning of the human platelet-derived growth factor receptor beta (PDGFR-beta) promoter and drug targeting of the G-quadruplex-forming region to repress PDGFR-beta expression. Biochemistry (2010) 1.06
The i-motif in the bcl-2 P1 promoter forms an unexpectedly stable structure with a unique 8:5:7 loop folding pattern. J Am Chem Soc (2009) 1.04
Tertiary DNA structure in the single-stranded hTERT promoter fragment unfolds and refolds by parallel pathways via cooperative or sequential events. J Am Chem Soc (2012) 1.02
The transcriptional complex between the BCL2 i-motif and hnRNP LL is a molecular switch for control of gene expression that can be modulated by small molecules. J Am Chem Soc (2014) 1.02
The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796. Bioorg Med Chem (2010) 1.01
UA62784, a novel inhibitor of centromere protein E kinesin-like protein. Mol Cancer Ther (2009) 1.01
High-throughput virtual screening identifies novel N'-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors. J Med Chem (2013) 0.98
Retracted Mutations in the G-quadruplex silencer element and their relationship to c-MYC overexpression, NM23 repression, and therapeutic rescue. Proc Natl Acad Sci U S A (2004) 0.97
Orally active alpha-tocopheryloxyacetic acid suppresses tumor growth and multiplicity of spontaneous murine breast cancer. Mol Cancer Ther (2009) 0.95
The role of G-quadruplex/i-motif secondary structures as cis-acting regulatory elements. Pure Appl Chem (2010) 0.94
S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther (2010) 0.94
Use of a bacteriophage lysin to identify a novel target for antimicrobial development. PLoS One (2013) 0.93
The vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancer. BMC Cancer (2011) 0.93
Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors. ACS Med Chem Lett (2011) 0.93
Laminin-5 beta3A expression in LNCaP human prostate carcinoma cells increases cell migration and tumorigenicity. Neoplasia (2004) 0.92
Comparing Aurora A and Aurora B as molecular targets for growth inhibition of pancreatic cancer cells. Mol Cancer Ther (2006) 0.91
Anticancer activity and cellular repression of c-MYC by the G-quadruplex-stabilizing 11-piperazinylquindoline is not dependent on direct targeting of the G-quadruplex in the c-MYC promoter. J Med Chem (2012) 0.89
Binding of G-quadruplex-interactive agents to distinct G-quadruplexes induces different biological effects in MiaPaCa cells. Nucleosides Nucleotides Nucleic Acids (2005) 0.89
Activators of PKM2 in cancer metabolism. Future Med Chem (2014) 0.89
A comprehensive strategy to combat colon cancer targeting the adenomatous polyposis coli tumor suppressor gene. Ann N Y Acad Sci (2005) 0.87
Molecular modeling and biophysical analysis of the c-MYC NHE-III1 silencer element. J Mol Model (2007) 0.86
I-motif structures formed in the human c-MYC promoter are highly dynamic--insights into sequence redundancy and I-motif stability. PLoS One (2010) 0.85
Determination of the importance of the stereochemistry of psorospermin in topoisomerase II-induced alkylation of DNA and in vitro and in vivo biological activity. Mol Cancer Ther (2005) 0.85
Identification of a novel inhibitor of urokinase-type plasminogen activator. Mol Cancer Ther (2007) 0.84
Structure of a quinobenzoxazine--G-quadruplex complex by REDOR NMR. Biochemistry (2004) 0.84
Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach. Mol Cancer Ther (2006) 0.84
Characterization of novel diaryl oxazole-based compounds as potential agents to treat pancreatic cancer. J Pharmacol Exp Ther (2009) 0.84
Targeting aurora2 kinase in oncogenesis: a structural bioinformatics approach to target validation and rational drug design. Mol Cancer Ther (2003) 0.84
Chemical genetic screen reveals a role for desmosomal adhesion in mammary branching morphogenesis. J Biol Chem (2012) 0.84
Design, synthesis, and biological evaluation of a series of fluoroquinoanthroxazines with contrasting dual mechanisms of action against topoisomerase II and G-quadruplexes. J Med Chem (2003) 0.83
A direct and nondestructive approach to determine the folding structure of the I-motif DNA secondary structure by NMR. J Am Chem Soc (2009) 0.83
TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase. Cancer Res (2013) 0.82
Structure-based design of novel anti-cancer agents targeting aurora kinases. Curr Med Chem Anticancer Agents (2003) 0.82
Modulating the functional contributions of c-Myc to the human endothelial cell cyclic strain response. J Vasc Res (2009) 0.82
p53-independent response to cisplatin and oxaliplatin in MMTV-ras mouse salivary tumors. Mol Cancer Ther (2003) 0.80
Pdx-1-driven overexpression of aurora a kinase induces mild ductal dysplasia of pancreatic ducts near islets in transgenic mice. Pancreas (2008) 0.80
DNA acting like RNA. Biochem Soc Trans (2011) 0.80
DNA structure: Visualizing the quadruplex. Nat Chem (2013) 0.80
In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2. Exp Hematol (2010) 0.79
Competitive enhancement of HGF-induced epithelial scattering by accessory growth factors. Exp Cell Res (2010) 0.78
Gaining insights into the small molecule targeting of the G-quadruplex in the c-MYC promoter using NMR and an allele-specific transcriptional assay. Top Curr Chem (2013) 0.77
Application of a novel [3+2] cycloaddition reaction to prepare substituted imidazoles and their use in the design of potent DFG-out allosteric B-Raf inhibitors. Bioorg Med Chem (2009) 0.76
Psorospermin structural requirements for P-glycoprotein resistance reversal. Mol Cancer Ther (2008) 0.75
3-[4-(10H-Indolo[3,2-b]quinolin-11-yl)piperazin-1-yl]propan-1-ol. Acta Crystallogr Sect E Struct Rep Online (2011) 0.75
Mutations in the G-quadruplex silencer element and their relationship to c-MYC overexpression, NM23 repression, and therapeutic rescue. Proc Natl Acad Sci U S A (2005) 0.75
Design, synthesis, and evaluation of psorospermin/quinobenzoxazine hybrids as structurally novel antitumor agents. J Med Chem (2003) 0.75
Patterns and Significance of PIM Kinases in Urothelial Carcinoma. Appl Immunohistochem Mol Morphol (2015) 0.75
Correction to "The Dynamic Character of the BCL2 Promoter i-Motif Provides a Mechanism for Modulation of Gene Expression by Compounds That Bind Selectively to the Alternative DNA Hairpin Structure". J Am Chem Soc (2016) 0.75
Potential mouse tumor model for pre-clinical testing of mage-specific breast cancer vaccines. Breast Cancer Res Treat (2002) 0.75
Conformationally restricted analogues of psorospermin: design, synthesis, and bioactivity of natural-product-related bisfuranoxanthones. J Med Chem (2005) 0.75